Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

APPROVALS ANALYSIS: Big Month For Cardio Devices, But Down Overall

This article was originally published in Clinica

Executive Summary

April was a slow month for medical device approvals, with just 46 recorded for the month on Clinica’s Medical Devices Approvals Tracker, but it was the biggest month for PMAs and PMA supplements approved by the US FDA in more than a year.

You may also be interested in...



MRI Labeling For Boston Scientific's Emblem MRI S-ICD Approved By US FDA

Boston Scientific cardiac rhythm management has been struggling to compete with MRI-compatible devices from rival Medtronic.

Earnings Winners And Losers: BSX, BCR, NUVA, NVCR

Several big names in medtech announced their second-quarter sales and earnings in late July and early August. Here are some of the companies that impressed investors and others that raised some doubts.

“We’re A Pain-Management Company.” Nevro Adds SI Joint Surgery To SCS Business

Nevro is known for its spinal cord stimulation technology but wants to help a wide range of patients with chronic pain, so it is buying Vyrsa, which offers a complete system for sacroiliac joint fusion. In and interview with Medtech Insight, Nevro CEO Kevin Thornal explained how  Vyrsa supports Nevro's strategy in this growing market.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103398

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel